Estimating the potential cost savings from the New York university caregiver intervention in Minnesota

Health Affairs

Volumn 33, Issue 4, 2014, Pages 596-604

  Long, Kirsten Hall ^a   Moriarty, James P ^b   Mittelman, Mary S ^c   Foldes, Steven S ^d,e  

^a K Long Consulting   (United States)

^b MAYO CLINIC   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Foldes Consulting   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT CHILD; ARTICLE; CAREGIVER; CAREGIVER SUPPORT; COMMUNITY LIVING; COST CONTROL; DEMENTIA; DISEASE COURSE; HEALTH CARE COST; HUMAN; INVESTMENT; PROGRAM COST EFFECTIVENESS; SPOUSE; UNITED STATES;

EID: 84898051919     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2013.1257     Document Type: Article

References (43)

1. Brookmeyer R, Evans DA, Hebert L, Langa KM, Heeringa SG, Plassman BL, et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 2011;7(1):61-73.
2. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14): 1326-34.
3. Department of Health and Human Services. National plan to address Alzheimer's disease: 2013 update [Internet]. Washington (DC): HHS; [cited 2014 Feb 13]. Available from: http://aspe.hhs.gov/daltcp/napa/ NatlPlan2013.pdf
4. National Institutes of Health [Internet]. Bethesda (MD): NIH. Press release, NIH funding boosts new Alzheimer's research on prevention, novel drug targets; 2013 Sep 18 [cited 2014 Feb 13]. Available from: http://www.nih.gov/news/health/ sep2013/nia-18.htm
5. Alzheimer's Association. Record $122 million increase for Alzheimer's disease signed into law by President Obama [Internet]. Chicago (IL): Alzheimer's Association; 2014 Jan 17 [cited 2014 Feb 13]. Available from: http://www.alz.org/ news_and_events_62779.asp
6. Alzheimer's Association. State government Alzheimer's disease plans [Internet]. Chicago (IL): Alzheimer's Association; [cited 2014 Feb 13]. Available from: http://act.alz.org/ site/PageNavigator/state_plans .html
7. Casey DA, Antimisiaris D, O'Brien J. Drugs for Alzheimer's disease: are they effective? P T. 2010;35(4): 208-11.
8. Ballard CG,Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006; (1):CD003476.
9. Gitlin LN. Good news for dementia care: caregiver interventions reduce behavioral symptoms in people with dementia and family distress. Am J Psychiatry. 2012;169(9):894-7.
10. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess. 2001;5(1): 1-137.
11. Brodaty H, Arasaratnam C. Metaanalysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012;169(9):946-53.
12. Alliance for Aging Research, Administration on Aging, MetLife Foundation. Translating innovation to impact: evidence-based interventions to support people with Alzheimer's disease and their caregivers at home and in the community [Internet]. Washington (DC): AOA; 2012 Sep [cited 2014 Feb 25]. (White Paper). Available from: http://www .aoa.gov/AoA_Programs/HPW/Alz_ Grants/docs/TranslatingInnovation toImpactAlzheimersDisease.pdf
13. Vickrey BG, Mittman BS, Connor KI, Pearson ML, Della Penna RD, Ganiats TG, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med. 2006;145(10): 713-26.
14. Boustani MA, Sachs GA, Alder CA, Munger S, Schubert CC, Guerriero Austrom M, et al. Implementing innovative models of dementia care: the Healthy Aging Brain Center. Aging Ment Health. 2011;15(1): 13-22.
15. Callahan CM, Boustani MA, Unverzagt FW, Austrom MG, Damush TM, Perkins AJ, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;295(18): 2148-57.
16. Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver wellbeing delays nursing home placement of patients with Alzheimer disease. Neurology. 2006;67(9): 1592-9.
17. Gaugler JE, Reese M, Mittelman MS. Effects of the NYU Caregiver Intervention-Adult Child on residential care placement. Gerontologist. 2013;53(6):985-97.
18. Nichols LO, Chang C, Lummus A, Burns R, Martindale-Adams J, Graney MJ, et al. The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56(3):413-20.
19. Gitlin LN, Belle SH, Burgio LD, Czaja SJ, Mahoney D, Gallagher-Thompson D, et al. Effect of multicomponent interventions on caregiver burden and depression: the REACH multisite initiative at 6-month follow-up. Psychol Aging. 2003;18(3):361-74.
20. Belle SH, Burgio L, Burns R, Coon D, Czaja SJ, Gallagher-Thompson D, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006;145(10):727-38.
21. Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease: a randomized controlled trial. JAMA. 1996;276(21): 1725-31.
22. Mittelman MS, Ferris SH, Steinberg G, Shulman E, Mackell JA, Ambinder A, et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. Gerontologist. 1993;33(6):730-40.
23. Mittelman M, Epstein C, Paone D, Walberg D. Alzheimer's disease support services program: a guide to implementing the New York University Caregiver Intervention and the Minnesota experience. St. Paul (MN): Minnesota Board on Aging; 2010.
24. Kokmen E, Cha RH, Rocca WA. Time trends in the prevalence of dementia and Alzheimer's disease in Rochester, Minnesota. In: Iqbal KI, Swaab DF, Winblad B, Wisniewski HM, editors. Alzheimer's disease and related disorders-etiology, pathogenesis, and therapeutics. Chichester (UK): John Wiley and Sons Ltd.; 1999. p. 3-7.
25. Knopman DS, Petersen RC, Cha RH, Edland SD, Rocca WA. Incidence and causes of nondegenerative nonvascular dementia: a population-based study. Arch Neurol. 2006;63(2): 218-21.
26. Minnesota Department of Administration. Dataset: Minnesota total population projections by age and gender, 2013-2060 [Internet]. St. Paul (MN): The Department; 2013 Feb 21 [cited 2014 Feb 13]. Available for download from: http:// www.demography.state.mn.us/ resource.html?Id=33109
27. Meng X, D'Arcy C. Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses. PLoS ONE. 2012;7(6):e38268.
28. Knopman DS, Petersen RC, Rocca WA, Larson EB, Ganguli M. Passive case-finding for Alzheimer's disease and dementia in two U.S. communities. Alzheimers Dement. 2011; 7(1):53-60.
29. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349(9068): 1793-6.
30. Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, et al. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology. 2001;57(6):957-64.
31. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8(2): 131-68.
32. To access the Appendix, click on the Appendix link in the box to the right of the article online.
33. Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Halls KH, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7(1):80-83.
34. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part 1. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989:39(9):1159-65.
35. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52(6):1138-45.
36. Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-ofinformation analysis. An application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care. 2001;17(1):38-55.
37. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Costeffectiveness of PET in the diagnosis of Alzheimer disease. Radiology. 2003;228(2):515-22.
38. Smith GE, O'Brien PC, Ivnik RJ, Kokmen E, Tangalos EG. Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology. 2001:57(8): 1467-73.
39. Leon J, Neumann PJ. The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care. 1999;5(7):867-77.
40. Dartmouth Atlas of Healthcare. Total Medicare reimbursements per enrollee, by adjustment type [Internet]. Lebanon (NH): Dartmouth Institute for Health Policy and Clinical Practice; [cited 2014 Feb 14]. Available from: http://www.dartmouth atlas.org/data/table.aspx?ind=225
41. Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med. 2013;369(24):2275-7.
42. Schubert CC, Boustani M, Callahan CM, Perkins AJ, Hui S, Hendrie HC. Acute care utilization by dementia caregivers within urban primary care practices. J Gen Intern Med. 2008; 23(11):1736-40.
43. Weimer DL, Sager MA. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes. Alzheimers Dement. 2009;5(3):215-26.